Latest Salix Pharmaceuticals Stories
Specialty pharmaceutical leader continues to drive efforts to help support growth as revenues surpass $1 billion with recent acquisition REDWOOD SHORES, Calif.
Salix Pharmaceuticals, a specialty pharmaceutical company, has announced that the FDA has granted marketing approval for Apriso extended-release capsules 0.375gm.
Salix Pharmaceuticals has initiated patient enrollment in Target 1 and Target 2, its Phase III, randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of rifaximin 550mg, dosed three times daily, in the treatment of subjects with non-constipation irritable bowel syndrome.
- To fire mitraille at.